Genomic testing through liquid biopsies plays a crucial role in detecting targetable lesions in solid tumors,43, 44, 45, 46 and this approach is equally relevant for IEM‐AML with the growing availability of targeted therapies, such as FLT3‐inhibitors, IDH1‐ and IDH2‐inhibitors, and Menin‐inhibitors.47 This evidence concerns the gene IDH2 and acute myeloid leukemia.